Full-Time

Sr. Research Associate

RNA Science

Posted on 9/10/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Junior, Mid, Senior

Cambridge, MA, USA

70% in-office structure required.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • BS or MS in Biology, Chemistry, Biochemistry, or Bioengineering-related field with at least 2 years of industry experience
  • Experience with mammalian cell culture and transfection techniques
  • Experience with protein and RNA quantification methods such as live cell imaging, western blotting, ELISA assays, and qPCR.
  • Ability to participate in multiple collaborative projects in a cross-functional team environment
  • Ability to multi-task to meet research goals
  • Strong quantitative analysis skills
  • Excellent written and oral communication
Responsibilities
  • Design, conduct and troubleshoot in vitro/ex vivo/cell-based RNA and protein experiments
  • Perform multiple biological techniques, including tissue culture, cell transfection, live cell imaging, qPCR, flow cytometry, western blots, ELISAs, capillary electrophoresis, and other biochemical assays.
  • Contribute to data analysis and interpretation of study results.
  • Interpret, summarize, and present experimental data and results at group meetings, project meetings, and department meetings.
  • Keep careful data records (electronic lab notebook and others)

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treatment options for patients. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the discovery, development, and manufacturing processes of medicines. The company's goal is to leverage the unique properties of mRNA to improve patient outcomes and create a new category of effective treatments.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's AI-driven drug discovery accelerates novel mRNA-based therapeutics identification.
  • Expansion in Asia enhances global supply chain and reduces production costs.
  • mRNA technology is gaining traction for non-infectious disease vaccines, like cancer.

What critics are saying

  • Potential Nasdaq 100 removal could impact stock visibility and investor interest.
  • Bypassing safety steps in Australia may raise regulatory and public scrutiny concerns.
  • Hong Kong's reluctance to receive Covid-19 jab affects market penetration and sales.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company focuses on mRNA's potential to transform drug discovery and manufacturing.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE